NYU Langone Health
This single-center, double-blind, placebo-controlled study will recruit in total 39 participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild Alzheimer's disease dementia (mild AD). There will be 3 Dose levels. An initial cohort of 13 subjects will be randomized to a Dose level 1 (0.1 mg/kg vs. placebo) lasting 8 weeks. An additional 13 subjects will be recruited and randomized into Dose level 2 (0.25 mg/kg vs. placebo) for 8 weeks and 13 subjects for the last Dose level 3 (0.5 mg/kg vs. placebo) for 8 weeks. The primary objective will be to assess safety and tolerability of CpG 1018.
Inclusion Criteria: 1. 65-85 years of age 2. MCI due to AD or mild AD dementia per NIA-AA specified criteria published in 2018 3. Montreal Cognitive Assessment (MoCA) score ≥17 AND; 4. Positive Florbetaben PET amyloid scan, or other positive PET amyloid scan performed within one year of study enrollment 5. Must be able to provide consent or assent (If applicable). 6. Must be willing and able to participate in all study related procedures. 7. Must have a reliable study partner to provide information on the subject's cognitive and functional status. Study partner must have sufficient contact wi…
0.1 mg/kg dose administered via subcutaneous injection. TLR9 agonist supplied by Dynavax Technologies Inc.
0.25 mg/kg dose administered via subcutaneous injection. TLR9 agonist supplied by Dynavax Technologies Inc.
0.5 mg/kg dose administered via subcutaneous injection. TLR9 agonist supplied by Dynavax Technologies Inc.
Sterile saline injection supplied by the NYU Investigational Pharmacy.
Arctuva estimate
Verify or correct the compensation shown for this listing.